CBIO

Crescent is a clinical-stage biotech with no approved products and no product revenue — by its own words, 'we do not have any products approved for sale and have not generated any revenue from product sales.' The $10.8M FY2025 revenue is legacy/contract revenue inherited via the reverse-recapitalization merger with GlycoMimetics, not a commercial engine, so the headline P/S of 43.4x is a meaningless artifact. The entire equity value rests on three unproven pipeline assets — CR-001 (a PD-1 x VEGF bispecific), CR-002 and CR-003 (ADCs) — all in or entering Phase 1/2. There is nothing in the fundamentals to value; this is a science-and-catalyst bet dressed as a stock.

The balance sheet is the one genuine strength: $213M cash against just $37.3M total liabilities and $203M equity (liabilities/equity 0.18x), post the merger and Private Placement that lifted total assets +575% and shares fell to 27.6M. But the burn is accelerating hard — R&D jumped +868% to $138M, operating loss hit -$153M, and operating cash flow was -$71.5M with three separate trials (CR-001 ASCEND, plus CR-002 and CR-003 starts) all launching through 2026. That $213M does not stretch far once all programs are dosing; a dilutive raise before the first meaningful data is a realistic risk for a company whose retained deficit is already -$172M.